Y-mAbs Therapeutics, Inc.
YMABDelisted Sep 16, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001722964
Y-mAbs Therapeutics, Inc. was delisted on Sep 16, 2025; its insiders filed their last Form 4 on Sep 19, 2025; 97 institutions reported holding it in 13F filings for Q2 2025, worth $125.9M in total; no superinvestor held it.
13F holders, Q3 2024
Institutional positions in Y-mAbs Therapeutics, Inc. as of Sep 30, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 105
- +10 vs. Q2 2024
- Shares held
- 25.7M
- +4.33M (+20.2%) vs. Q2 2024
- Total value
- $338.5M
- +$79.9M (+30.9%) vs. Q2 2024
- New holders
- 20
- 37 more added
- Sold out
- 10
- 28 more reduced
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting YMAB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 2 | $78.3K |
| Q2 2025 | 97 | $125.9M |
| Q1 2025 | 103 | $127.6M |
| Q4 2024 | 113 | $225.5M |
| Q3 2024 | 105 | $338.5M |
| Q2 2024 | 96 | $294.2M |
| Q1 2024 | 96 | $374.0M |
| Q4 2023 | 94 | $138.0M |
| Q3 2023 | 99 | $107.3M |
| Q2 2023 | 95 | $132.4M |
| Q1 2023 | 86 | $95.4M |
| Q4 2022 | 91 | $94.2M |
| Q3 2022 | 100 | $339.7M |
| Q2 2022 | 91 | $374.7M |
| Q1 2022 | 88 | $300.6M |
| Q4 2021 | 97 | $417.1M |
| Q3 2021 | 97 | $749.0M |
| Q2 2021 | 100 | $886.9M |
| Q1 2021 | 117 | $804.8M |
Institutions, Q3 2024
Shares, value and share of portfolio for each institution holding Y-mAbs Therapeutics, Inc.; share changes are against Q2 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Polar Capital Holdings Plc | 1,831,000 | $24.1M | 0.14% | 00.0% | Unchanged |
| Vanguard Group Inc | 2,035,363 | $26.8M | 0.00% | +78,024+4.0% | Added |
| Sofinnova Investments, Inc. | 2,194,278 | $28.9M | 2.39% | 00.0% | Unchanged |
| BlackRock, Inc. | 3,025,235 | $39.8M | 0.00% | +3,025,235 | New |
| Paradigm Biocapital Advisors LP | 4,086,346 | $53.7M | 1.88% | +215,752+5.6% | Added |
| Massachusetts Financial Services Co | 0 | $0 | 0.00% | −82,202−100.0% | Sold out |
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −43,973−100.0% | Sold out |
| Sherbrooke Park Advisers LLC | 0 | $0 | 0.00% | −23,647−100.0% | Sold out |
| Cubist Systematic Strategies, LLC | 0 | $0 | 0.00% | −6,597−100.0% | Sold out |
| Danske Bank A/S | 0 | $0 | 0.00% | −1,276−100.0% | Sold out |
| HighMark Wealth Management LLC | 0 | $0 | 0.00% | −220−100.0% | Sold out |
| Russell Investments Group, Ltd. | 0 | $0 | 0.00% | −188−100.0% | Sold out |
| Signaturefd, LLC | 0 | $0 | 0.00% | −64−100.0% | Sold out |
| Point72 (DIFC) Ltd | 0 | $0 | 0.00% | −53−100.0% | Sold out |
| Advisor Group Holdings, Inc. | 0 | $0 | 0.00% | −30−100.0% | Sold out |
| BlackRock Inc. | – | – | – | – | Not filed |